Related Experiment Video

Updated: May 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

The role of MICAL2 in cancer progression: mechanisms, challenges, and therapeutic potential

Ruiying Wang1, Zhijuan Hou1, Xiao Gao1

  • 1Nuclear Industry 215 Hospital of Shaanxi Province, Shaanxi, China.

Human Cell
|April 16, 2025
PubMed

Insights

Molecule interacting with CasL 2 (MICAL2) promotes cancer progression by inducing epithelial-mesenchymal transition (EMT). Understanding MICAL2

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer remains a significant global health challenge, driving the search for targeted therapies beyond conventional chemotherapy.
  • Molecule interacting with CasL 2 (MICAL2), a flavin-dependent monooxygenase, plays roles in cellular processes including cytoskeletal regulation and apoptosis.
  • Emerging evidence suggests MICAL2's involvement in tumorigenesis and cancer progression.

Purpose of the Study:

  • To review the biological functions of MICAL2 in the context of cancer.
  • To elucidate the molecular mechanisms by which MICAL2 promotes cancer progression.
  • To discuss the therapeutic potential and future directions for targeting MICAL2 in cancer treatment.

Main Methods:

  • Literature review of recent research findings on MICAL2 and cancer.
  • Analysis of MICAL2's role in cytoskeletal dynamics and redox regulation.
  • Investigation of MICAL2's impact on signaling pathways such as SRF/MRTF-A and semaphorin/plexin.

Main Results:

  • MICAL2 induces F-actin depolymerization via REDOX modification, promoting epithelial-mesenchymal transition (EMT).
  • MICAL2 upregulates EMT-related proteins, enhancing cancer cell invasion and proliferation.
  • MICAL2 is highly expressed in tumors and acts as a novel tumor-promoting factor.

Conclusions:

  • MICAL2 significantly contributes to cancer progression through the induction of EMT via specific signaling pathways and ROS production.
  • MICAL2 represents a promising molecular target for developing novel cancer therapies.
  • Further research into MICAL2's mechanisms and clinical targeting is warranted.
Keywords:
CancerMetastasisMolecule interacting with CasL 2 (MICAL2)ProliferationTargeted therapy

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.3K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K